arrow
A

Ania M. Jastreboff

Yale University School of Medicine
H指数:33
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Obesity Pharmacotherapy An Urgent Need for Progressing Science, Access, and Equity- JACC: Advances Expert Panel

肥胖药物治疗:科学进展、可及性和公平性的迫切需求 - JACC: Advances 专家小组

2026-05-010
OA
Clinical profile and long-term outcomes of chest pain patients with coronary microvascular dysfunction from the emergency department – results from the Yale-CMD registry

急诊科冠状动脉微血管功能障碍的胸痛患者的临床特征及长期预后——耶鲁-CMD注册研究的结果

2025-10-170
PRE
Toward Health Equity: A Workshop Report on the State of the Science of Obesity Interventions for Adults

迈向健康公平:成人肥胖干预措施科学现状研讨会报告

OBESITY
IF4.7
2025-09-010
OAAI
DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

DCRM 2.0: 糖尿病,心脏和代谢疾病管理的多专业实践建议

2024-10-015
OA
Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial

SELECT试验中,司美鲁肽对超重或肥胖但无糖尿病患者血糖消退和进展的影响

2024-06-227
OAAI
Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey

基于选择试验标准的美国心血管风险降低治疗的资格: 来自国家健康和营养检查调查的见解

2024-01-013
OAAI
Reflecting on a Year at the Helm of Diabetes Care

反思糖尿病护理掌舵的一年

2023-12-200
OA
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

每周一次Tirzepatide用于治疗2型糖尿病患者的肥胖症 (SURMOUNT-2): 一项双盲,随机,多中心,安慰剂对照的3期试验

LANCET
IF88.5
2023-08-01211
OAAI